Skip to main content
. 2020 Jan 23;122(6):857–867. doi: 10.1038/s41416-019-0704-2

Fig. 3. Survival analysis in resectable PDAC patients with or without plasma KRAS G12D mutation in the validation cohort.

Fig. 3

a OS for resectable PDAC patients with (n = 5, red) and without (n = 39, blue) KRAS G12D mutant in ctDNA. b RFS for resectable PDAC patients with (n = 5, red) and without (n = 39, blue) KRAS G12D mutation in ctDNA.